
Black Diamond Therapeutics, a US-based biotech firm, develops precision medicines for genetically-defined cancers.
Black Diamond Therapeutics is a biotechnology company focused on developing precision medicines for genetically-defined cancers. Their core mission is to address broad patient populations with their innovative MasterKey therapies, which are designed to overcome cancer resistance, minimize wild-type mediated toxicities, and penetrate the brain to treat central nervous system diseases. The company primarily serves the United States market.
Black Diamond Therapeutics has made significant strides in cancer treatment, including presenting promising clinical data for their BDTX- therapy in patients with recurrent glioblastoma at the American Society of Clinical Oncology Annual Meeting. Their impact is underscored by their commitment to developing effective treatments for challenging cancer types, contributing to advancements in precision medicine.

Obsidian Therapeutics
obsidiantx.com

Blueprint Medicines

Kronos Bio

Praxis Precision Medicines

Checkpoint Therapeutics
checkpointtx.com

G1 Therapeutics
g1therapeutics.com

Signet Therapeutics

Scorpion Therapeutics

Tango Therapeutics
tangotx.com

Window Therapeutics
windowtx.com

Palm Therapeutics

Whitehawk Therapeutics
aadibio.com

Duet BioTherapeutics

Advanced Cancer Therapeutics

GO Therapeutics
gotherapeutics.com
Companies similar to Black Diamond Therapeutics include Obsidian Therapeutics, Blueprint Medicines, Kronos Bio and Praxis Precision Medicines.
Black Diamond Therapeutics was founded in 2017.
Black Diamond Therapeutics' headquarters is located in Cambridge, MA, US.
Black Diamond Therapeutics' most recent funding round was for $75M (USD) in June 2023.
As of Jun 29, 2023, Black Diamond Therapeutics has raised a total of $272.1M (USD).
Black Diamond Therapeutics has 65 employees as of Feb 12, 2024.